Holen Sie sich die Stockscreener-App
0.984
2.34%
0.0225
Handel nachbörslich:
.99
0.006
+0.61%
Oncolytics Biotech Inc Aktie (ONCY) Neueste Nachrichten
Insider Buying: Oncolytics Biotech (NASDAQ:ONCY) Director Purchases 10,000 Shares of Stock - MarketBeat
Insider Buying: James Parsons Acquires Additional Shares of Oncolytics Biotech Inc (ONCY) - GuruFocus
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
What is Oncolytics Biotech Incs 5 year growth outlookProduct Launch & Verified Swing Trading Watchlists - baoquankhu1.vn
How Oncolytics Biotech Inc. stock compares to market leadersProfit Target & Step-by-Step Swing Trade Plans - Naître et grandir
ONCY Stock Rallies On Second Fast Track Designation For Experimental Cancer Drug - Stocktwits
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types - marketscreener.com
Oncolytics Biotech Advances Pelareorep Into New Phase 2 Colorectal Cancer Study - TipRanks
Cancer Treatment Breakthroughs Stack Up as Clinical Pipelines Advance - Baystreet.ca
Earnings Report: Is Oncolytics Biotech Inc undervalued by DCF analysisJuly 2025 Drop Watch & Accurate Buy Signal Notifications - baoquankhu1.vn
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion - Cantech Letter
Oncolytics Biotech Launches Randomized Phase 2 REO-033 Trial for Pelareorep in RAS-Mutant MSS Metastatic Colorectal Cancer — With FDA Fast Track Behind It - Oncodaily
Oncolytics launches phase 2 colorectal cancer study REO 033 By Investing.com - Investing.com Canada
Oncolytics launches phase 2 colorectal cancer study REO 033 - Investing.com
Oncolytics Biotech Launches Phase 2 Colorectal Cancer Trial - TipRanks
Oncolytics Biotech Launches Randomized Colorectal Cancer Study - Bitget
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech (NASDAQ: ONCY) launches Phase 2 pelareorep colorectal cancer study - Stock Titan
Oncolytics Biotech Inc initiates phase 2 study for metastatic colorectal cancer - marketscreener.com
Oncolytics (ONCY) Initiates Phase 2 Trial for Metastatic Colorec - GuruFocus
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study - The Manila Times
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Enrollment Milestone - simplywall.st
Oncolytics Biotech Refocuses On Rare Cancers After GOBLET Milestone - Sahm
Oncolytics Biotech (ONCY) Expected to Announce Earnings on Friday - MarketBeat
Oncolytics Biotech rises as U.S. FDA clears path for pancreatic cancer trial - TradingView
Lake Street Sticks to Their Buy Rating for Oncolytics Biotech (ONCY) - The Globe and Mail
Oncolytics Biotech gains as enrollments for GIT cancer trial conclude - MSN
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 - Cantech Letter
Oncolytics to wind down GOBLET study, focus on U.S. registration - Investing.com India
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge - The Malaysian Reserve
Death Cross: Will Oncolytics Biotech Inc outperform the market in YEARJuly 2025 Earnings & Short-Term Swing Trade Alerts - baoquankhu1.vn
Oncolytics Biotech (ONCY) Ends Enrollment in GOBLET Study to Foc - GuruFocus
Oncolytics to wind down GOBLET study, focus on U.S. registration By Investing.com - Investing.com Canada
Oncolytics to stop enrollments for GIT cancer trial (ONCY) - Seeking Alpha
Oncology Market Set to Nearly Triple: Here Are Five Companies Le - GuruFocus
Oncolytics (ONCY) Completes Enrollment in GOBLET Study, Advances Cancer Research - GuruFocus
Cancer Drug Market on Track to Double by 2033: Five Oncology Plays to Watch - Baystreet.ca
Oncolytics Refocuses Pipeline on Key GI Cancer Programs - TipRanks
Oncolytics Biotech (ONCY) pivots to registration-focused anal and colorectal cancer trials - Stock Titan
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer - GlobeNewswire
Can Oncolytics Biotech Inc expand its profit marginsQuarterly Profit Summary & Growth Focused Stock Reports - baoquankhu1.vn
Trading Recap: How sensitive is Oncolytics Biotech Inc to inflationWeekly Loss Report & Verified Trade Idea Suggestions - baoquankhu1.vn
Risk Off: Is Oncolytics Biotech Inc undervalued by DCF analysis2025 Trading Recap & Community Consensus Trade Signals - baoquankhu1.vn
What are Oncolytics Biotech Inc.’s earnings expectationsPortfolio Performance Summary & Low Risk High Reward Ideas - mfd.ru
Patterns Watch: How is Oncolytics Biotech Inc managing supply chain issuesJuly 2025 PreEarnings & Community Consensus Trade Signals - baoquankhu1.vn
Aug Spikes: Can Oncolytics Biotech Inc expand its profit marginsMarket Trend Summary & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Big Money Moves: What drives CRWDs stock price2025 Valuation Update & Entry Point Confirmation Signals - baoquankhu1.vn
THE INFRASTRUCTURE REALIGNMENT: 5 Stocks Positioning for the 2026 Supply Imperative - The Globe and Mail
Smart Money: What is Oncolytics Biotech Incs 5 year growth outlookMarket Movers & Community Verified Trade Signals - baoquankhu1.vn
Registration Momentum Builds Across the Oncology Pipeline - The Globe and Mail
Public market insider buying at Oncolytics Biotech (ONC) - The Globe and Mail
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):